Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue from contracts with customers (Details)

v3.24.3
Revenue - Revenue from contracts with customers (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
contract
Sep. 30, 2023
USD ($)
contract
Sep. 30, 2024
USD ($)
contract
Sep. 30, 2023
USD ($)
contract
Dec. 31, 2023
USD ($)
Revenue          
Revenue $ 40,901,000 $ 7,319,000 $ 174,810,000 $ 60,050,000  
Number of contracts with customers | contract 3 2 3 3  
Deferred revenue decrease         $ 60,593,000
Deferred revenue $ 117,440,000   $ 117,440,000   $ 178,033,000
Amount of increase in deferred income caused by the change in the exchange rate     $ 9,130,000    
Exchange rate 1.34   1.34   1.27
Aggregate amount of the transaction price that is allocated to performance obligations $ 128,150,000   $ 128,150,000    
Revenue recognized in the period     161,007,000    
Development revenue          
Revenue          
Revenue 40,901,000 $ 7,319,000 174,810,000 $ 60,050,000  
Commercial Sales          
Revenue          
Revenue $ 0   0    
Galapagos Collaboration and Exclusive License Agreement          
Revenue          
Milestone payments received     85,000,000    
GSK Collaboration And License Agreement          
Revenue          
Milestone payments received     $ 9,673,000